University of California, San Diego Moores Cancer Center
Welcome,         Profile    Billing    Logout  
 60 Trials 
107 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Read, William H
NCT03233698: Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery

Recruiting
2
26
US
Atezolizumab, Laboratory Biomarker Analysis, Pharmacological Study
National Cancer Institute (NCI)
Metastatic Alveolar Soft Part Sarcoma
12/18
12/18
ZIABC011078, NCT03141684: Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

Hourglass Oct 2024 - Dec 2024 : Regulatory approval for alveolar soft part sarcoma
Active, not recruiting
2
63
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography
National Cancer Institute (NCI)
Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
10/25
10/25
NCT04590664: Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

Recruiting
1/2
24
US
Verteporfin, Benzoporphyrin Derivative Monoacid Ring A, BPD-MA, Visudyne
Emory University, National Cancer Institute (NCI)
Glioblastoma, Recurrent Glioblastoma
08/25
08/25
Daniels, Gregory A
IGNYTE-3, NCT06264180: VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs

Recruiting
3
400
US
Vusolimogene Oderparepvec, VO, RP1, Nivolumab, Opdivo, Nivolumab + Relatlimab, Opdualag, Pembrolizumab, Keytruda, Single-agent chemotherapy
Replimune Inc.
Advanced Melanoma
01/29
08/34
NCI-2020-07748, NCT04598009: Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

Recruiting
2
25
US
Binimetinib, Binimetinib Oral, Mektovi, ARRY-162, MEK162, Imatinib, Imatinib Mesylate
University of California, San Francisco, Array BioPharma
Melanoma Stage III, Melanoma Stage IV
07/25
03/27
NCT03991130: High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

Terminated
2
6
US
IL-2 and Nivolumab, High Dose IL-2, Anti-PD-1
Gregory Daniels
Melanoma Stage Iv, Renal Cell Carcinoma, Metastatic
01/25
01/25
IGNYTE, NCT03767348 / 2016-004548-12: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Hourglass Jan 2024 - Mar 2024 : Data from IGNYTE trial in combination with Opdivo for 2L melanoma
Checkmark From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Nov 2020 - Nov 2020: From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Checkmark Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Nov 2019 - Nov 2019: Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Recruiting
2
340
Europe, US
RP1, nivolumab, Opdivo
Replimune Inc., Bristol-Myers Squibb
Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
12/25
12/28
NCT04157517: A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Terminated
1/2
45
US, RoW
Modakafusp Alfa, TAK-573, Pembrolizumab
Takeda
Neoplasms, Melanoma
12/23
12/23
XTX202-01, NCT05052268 / 2022-003078-21: XTX202 in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
189
US
XTX202
Xilio Development, Inc., Xilio Development, Inc
Advanced Solid Tumor
02/26
02/26
OMNIA-1, NCT05578872 / 2021-006711-29: A Study of ANV419 Alone or in Combination with Approved Treatment in Patients with Cutaneous Melanoma ().

Completed
1/2
29
Europe, US
ANV419, Pembrolizumab, Ipilimumab
Anaveon AG, Anaveon AG
Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma
08/24
08/24
NCT05580770: Mirdametinib + BGB-3245 in Advanced Solid Tumors

Active, not recruiting
1/2
23
US, RoW
Mirdametinib, PD-0325901, BGB-3245
SpringWorks Therapeutics, Inc.
Advanced Solid Tumor
10/26
06/27
ARTACUS, NCT04349436: A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies

Recruiting
1/2
65
US
RP1, intra-tumoral injection, oncolytic virus
Replimune Inc.
Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Melanoma
09/27
01/28
NCT03991741: Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Recruiting
1
24
US
Autologous Tumor Infiltrating Lymphocytes, High-Dose Interleukin 2
Gregory Daniels, Immunotherapy Foundation
Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
08/24
08/26
MAST, NCT05346484: A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors

Recruiting
1
100
US, RoW
CF33-hNIS, VAXINIA, HOV2, Pembrolizumab, KEYTRUDA®
Imugene Limited
Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer, Advanced Solid Tumor, Cholangiocarcinoma, Bile Duct Cancer
12/24
01/25
Kipps, Thomas J
NCT01199575: Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Completed
2
30
US
Revlimid, lenalidomide, Rituximab, Rituxan
University of California, San Diego, Celgene Corporation
Chronic Lymphocytic Leukemia, CLL
01/15
07/22
NCT02315768: Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

Active, not recruiting
1/2
32
US
GA101, Obinutuzumab, ibrutinib
University of California, San Diego, Pharmacyclics LLC.
Chronic Lymphocytic Leukemia
11/23
11/23
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
Castro, Januario
NCT04629729: FT819 in Subjects With B-cell Malignancies

Active, not recruiting
1
54
US
FT819, Cyclophosphamide, Fludarabine, Fludara, IL-2, Interleukin-2, Bendamustine, Bendeka, Treanda
Fate Therapeutics
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
09/24
09/39
McHale, Michael T
OnPrime, NCT05281471: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (, GOG-3076)

Recruiting
3
186
US
olvimulogene nanivacirepvec, GL-ONC1 and GLV-1h68, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
Genelux Corporation, GOG Foundation
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
08/25
10/26
HOTT, NCT05659381: Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Recruiting
3
230
US
Cisplatin, Platinol AQ, No treatment
GOG Foundation, GlaxoSmithKline
Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
08/29
08/34
ROCKIF, NCT03287271: Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

Recruiting
1/2
90
US
VS-6063, defactinib, Paclitaxel, Taxol, Carboplatin, Paraplatin
Michael McHale, Verastem, Inc., Nine Girls Ask
Ovarian Cancer
04/25
04/26
OVATION 2, NCT03393884: Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer

Checkmark Presentation of OVATION 2 data in advanced ovarian cancer
Mar 2021 - Mar 2021: Presentation of OVATION 2 data in advanced ovarian cancer
Active, not recruiting
1/2
130
Canada, US
IMNN-001, Carboplatin, Paclitaxel
Imunon
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
07/24
11/25
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
Kesari, Santosh
NCT02833792: Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease

Recruiting
2a
40
US
Human Mesenchymal Stem Cells and Lactated Riunger's Solution, Placebo
Stemedica Cell Technologies, Inc., Stemedica International SA
Alzheimer Dementia
07/24
12/24
NCT04780685: A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19

Recruiting
2
40
US
hMSC, allogeneic mesenchymal bone marrow cells
Stemedica Cell Technologies, Inc., bioRASI, LLC
Covid19
09/22
12/22
NCT02847559: Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Recruiting
2
27
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Electric Field Therapy, NovoTTF-200A Device, NovoTTF-200A, NovoTTF-200A System, NovoTTFields, NovoTumor Treatment Fields, Optune, Optune Device, Quality-of-Life Assessment, Quality of Life Assessment
Northwestern University, NovoCure Ltd., National Cancer Institute (NCI)
Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma, Supratentorial Meningioma
09/26
12/26
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
12/24
03/25
IORT, NCT04681677: Recurrent GBM Treated With Neurosurgical Resection and Using the Xoft Axxent eBx System and Bevacizumab

Terminated
2
12
US
Radiation: Intra-operative Radiation Therapy - IORT, Bevacizumab, Avastin
Xoft, Inc., Icad, Inc.
Glioblastoma, Recurrent Glioblastoma, GBM, Recurrent GBM
04/24
04/24
DIET2TREAT, NCT05708352: A Phase 2 Study of the Ketogenic Diet Vs Standard Anti-cancer Diet Guidance for Patients with Glioblastoma in Combination with Standard-of-care Treatment

Recruiting
2
170
US
Keto Diet, Standard Anti-Cancer Diet
Cedars-Sinai Medical Center, National Cancer Institute (NCI)
Glioblastoma Multiforme
06/28
06/29
NCT03955042: Pemetrexed for the Treatment of Chordoma

Completed
1
15
US
Pemetrexed, Alimta
Saint John's Cancer Institute, Eli Lilly and Company, Chordoma Foundation
Chordoma
07/22
01/23
NCT03425292: A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

Completed
1
49
US
Temozolomide, temodar, conformal brain radiation therapy, Nivolumab, opdivo, Ipilimumab, yervoy, Bevacizumab, avastin, 5-day Temozolomide, Lomustine, CCNU, Nivolumab monotherapy
Saint John's Cancer Institute
Newly Diagnosed High Grade Glioma
09/22
10/23
NCT05561374: Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma

Active, not recruiting
1
16
US
Low-dose OKN-007, BID, Low-dose OKN-007, TID, Mid-dose OKN-007, TID, High-dose OKN-007, TID
Oblato, Inc.
High-grade Glioma, Oligodendroglioma, Astrocytoma, Glioblastoma Multiforme
05/25
06/25
NCT06404034: Expanded Access to Gallium Maltolate (GaM)

Available
N/A
US
Gallium Maltolate, GaM
Imaging Biometrics, LLC, xCures
Glioblastoma, Refractory Glioblastoma, Glioblastoma Multiforme
 
 
Lowy, Andrew
NCT03659448 / 2018-000151-40: Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

Recruiting
3
300
Europe, US
SGM-101
Surgimab
Colorectal Neoplasms
11/24
12/24
A021806, NCT04340141: Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Recruiting
3
352
Canada, US
Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil, Resection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer
01/26
11/30
NCT06639724: Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

Recruiting
1
36
US
Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
University of California, San Diego, Rigel Pharmaceuticals
Pancreatic Ductal Adenocarcinoma (PDAC)
06/27
12/28
Piccioni, David
NCT00887146 / 2008-007295-14: Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Active, not recruiting
3
305
Europe, Canada, US
concomitant temozolomide (TMZ), radiotherapy, procarbazine, adjuvant temozolomide (TMZ), CCNU, vincristine
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), European Organisation for Research and Treatment Center (EORTC), Canadian Cancer Trials Group
Brain and Central Nervous System Tumors
10/25
10/25
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT04145115: A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

Suspended
2
37
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma, Glioblastoma, IDH-Wildtype, Secondary Glioblastoma
05/25
05/25
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
12/24
03/25
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
NCT03994796: Genetic Testing in Guiding Treatment for Patients with Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/26
06/28
NCT03173950: Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Active, not recruiting
2
108
US
Nivolumab
National Cancer Institute (NCI)
Medulloblastoma, Ependymoma, Pineal Region Tumors, Choroid Plexus Tumors, Atypical/Malignant Meningioma
07/25
07/26
NCT05432804: Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Recruiting
1/2
97
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT 330, KPT-330, KPT330, Nexpovio, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
National Cancer Institute (NCI)
MGMT-Methylated Glioblastoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
06/26
06/26
NCT05664243: A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
4
US
Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma-delta T cells
In8bio Inc.
Glioblastoma
12/25
12/25
NCT05634707: Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

Recruiting
1
30
US
Fluoxetine, Temozolomide
Duke University
Primary Brain Tumor, Brain Tumor, Recurrent
12/26
06/27
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26
NCT04427384: Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)

Recruiting
N/A
600
US
GammaTile
GT Medical Technologies, Inc.
Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Adult Meningioma
10/28
12/28
McKay, Rana
PDIGREE, NCT03793166: Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The Study

Checkmark Initiated in combination with nivolumab and ipilimumab for 1L RCC
Jan 2019 - Jan 2019: Initiated in combination with nivolumab and ipilimumab for 1L RCC
Active, not recruiting
3
1175
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Malignant Neoplasm in the Viscera, Rhabdoid Tumor of the Kidney, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
09/25
09/25
BEFORE, NCT06651697: BladdEr Full OR Empty for Pelvic Radiation Therapy

Recruiting
3
300
US
Radiation therapy
University of California, San Diego
Pelvic Neoplasm
04/28
12/29
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
SGNTUC-019, NCT04579380 / 2020-004873-29: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Active, not recruiting
2
217
Europe, Japan, US, RoW
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex
Seagen Inc., Seagen, Inc.
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
11/23
05/25
NePtune, NCT05498272: Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

Recruiting
2
32
US
Olaparib, Lynparza, LHRH agonist, Goserelin, Triptorelin, Leuprolide
Rana McKay, MD, AstraZeneca, University of California, San Diego
Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
12/25
12/26
CANOPY, NCT05502315: Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

Recruiting
2
50
US
Cabozantinib, Cabometyx, Nivolumab, Opdivo
Rana McKay, MD, Exelixis, Bristol-Myers Squibb
Castration-resistant Prostate Cancer, Metastatic Cancer
04/26
04/27
NCT03333616: Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Checkmark In combination with Yervoy for advanced genitourinary cancers
May 2020 - May 2020: In combination with Yervoy for advanced genitourinary cancers
Checkmark In combination with Opdivo for advanced genitourinary cancers
May 2020 - May 2020: In combination with Opdivo for advanced genitourinary cancers
Active, not recruiting
2
100
US
Ipilimumab, Yervoy, Nivolumab, Opdivo
Dana-Farber Cancer Institute, Bristol-Myers Squibb
Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder, Non-urothelial Upper Tract, Penile Cancer, Non-adenocarcinoma Prostate Cancer, Refractory Germ-cell, High Grade Neuroendocrine Carcinoma/Small Cell Carcinoma
12/24
05/25
NCT04126070: Nivolumab + Docetaxel + ADT in MHSPC Patients with DDRD or Inflamed Tumors

Active, not recruiting
2
60
US
Androgen Deprivation Therapy, Leuprolide, Lupron Depot, Goserelin acetate, Zoladex, Degarelix, Firmagon, Nivolumab, Docetaxel, Taxotere
Xiao X. Wei, MD, Bristol-Myers Squibb
Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma
10/24
06/25
ARACOG, NCT04335682: Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

Recruiting
2
132
US
Darolutamide, Nubeqa, Enzalutamide, Xtandi
Alliance Foundation Trials, LLC., Bayer
Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer, Castrate Resistant Prostate Cancer, Hormone Sensitive Prostate Cancer, Non-metastatic Prostate Cancer
08/25
08/26
NCI-2017-02296, NCT03375307: Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

Recruiting
2
150
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma, Metastatic Bladder Carcinoma, Metastatic Genitourinary System Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
12/25
12/25
RadiCal, NCT04071223: Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Recruiting
2
134
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radium Ra 223 Dichloride, Alpharadin, BAY 88-8223, BAY88-8223, Radium 223 Dichloride, RADIUM RA-223 DICHLORIDE, Radium-223 Chloride, Radium-223 Dichloride, Xofigo
National Cancer Institute (NCI)
Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
10/25
10/25
PREDICT, NCT06632977: Targeted Treatment for Metastatic Prostate Cancer, The Trial

Not yet recruiting
2
474
US
Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging, MRI, Computed Tomography, CAT Scan, CT Scan, Bone scan, FDG-Positron Emission Tomography, PSMA PET Scan, Prostate-specific Membrane Antigen PET, Biospecimen Collection, Carboplatin, Cabazitaxel, Abiraterone Acetate, Enzalutamide, Xtandi, Lutetium Lu 177 Vipivotide Tetraxetan, Pluvicto
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
04/30
10/34
NCT04363164: Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Recruiting
2
150
US
Testosterone cypionate, Depo-Testosterone Injection, Enzalutamide, Testosterone enanthate, Delatestryl
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, United States Department of Defense
Castration Resistant Metastatic Prostate Cancer
07/25
07/26
NCT05327010: Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Recruiting
2
88
US
BET Bromodomain Inhibitor ZEN-3694, BETi ZEN-3694, ZEN 3694, ZEN-3694, ZEN003694, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Diagnostic Imaging, Medical Imaging, Talazoparib, BMN 673, BMN-673, BMN673
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
08/25
08/25
ARCITECT, NCT05928806: Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

Recruiting
2
120
US
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Ipilimumab, Yervoy, Nivolumab, Opdivo
Michael B. Atkins, MD, Agenus Inc., Georgetown University
Advanced Renal Cell Carcinoma
10/25
10/26
NKT2152-202, NCT05935748: Ph2 Study NKT2152 with Palbociclib & Sasanlimab in Subjects with Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Active, not recruiting
2
172
US
NKT2152, palbociclib, IBRANCE®, sasanlimab
NiKang Therapeutics, Inc., Pfizer
CcRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Carcinoma, Neoplasms, Carcinoma, Renal Cell, Neoplasms, Glandular and Epithelial, Neoplasm by Histology, Adenocarcinoma, Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Kidney Diseases, Urologic Diseases
06/25
06/26
COMRADE, NCT03317392: Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

Active, not recruiting
1/2
133
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Quality-of-Life Assessment, Quality of Life Assessment, Radium Ra 223 Dichloride, Alpharadin, BAY 88-8223, BAY88-8223, Radium 223 Dichloride, RADIUM RA-223 DICHLORIDE, Radium-223 Chloride, Radium-223 Dichloride, Xofigo
National Cancer Institute (NCI)
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
04/25
04/25
DRAGON, NCT04291079: SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
112
US, RoW
SRK-181, anti-PD-(L)1 antibody therapy
Scholar Rock, Inc.
Cancer
12/24
12/24
MK-6482-030, NCT06234605: A Study of HC-7366 in Combination With Belzutifan (WELIREGâ„¢) in Patients With Renal Cell Carcinoma

Recruiting
1
80
US
HC-7366, Belzutifan, WELIREGâ„¢, MK-6482
HiberCell, Inc., Merck Sharp & Dohme LLC
Renal Cell Carcinoma
11/26
11/27
CirmD, NCT05156905: Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer

Terminated
1
6
US
Cirmtuzumab, Docetaxel
University of California, San Diego
Metastatic Castration-resistant Prostate Cancer
10/24
10/24
STK-012-101, NCT05098132: STK-012 Monotherapy and in Combination Therapy in Patients with Solid Tumors

Recruiting
1
202
US
STK-012, pembrolizumab, pemetrexed, carboplatin
Synthekine
Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Cervical Cancer, Microsatellite Instability High, Gastric Cancer, GastroEsophageal Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
10/27
10/27
IMPRINT, NCT05470036: Improving Germline Testing in At-Risk Patients With Prostate Cancer

Active, not recruiting
N/A
50
US
Educational intervention.
University of California, San Diego
Prostate Cancer
06/25
12/25
IRONMAN, NCT03151629: International Registry for Men With Advanced Prostate Cancer

Recruiting
N/A
5000
Europe, Canada, US, RoW
Standard of Care
Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/31
01/32
Manager, Project
MAGNAM, NCT05287191: Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care

Recruiting
3
200
Canada
Magnesium sulfate and then Digoxin, Amiodarone
Sunnybrook Health Sciences Centre, Sunnybrook Research Institute
Atrial Fibrillation New Onset
10/25
04/26
LANTERN, NCT06702878: Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections

Recruiting
3
4514
US
nasal antimicrobial photodisinfection therapy
Ondine Biomedical Inc.
Surgical Site Infections, Surgical Wound Infection, Infections, Anti-Infective Agents
07/25
08/25
PEMDA-HN, NCT05814666: Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

Recruiting
2
81
Europe, US, RoW
Danvatirsen, ISIS 481464, AZD9150, Pembrolizumab, Keytruda
Flamingo Therapeutics NV
HNSCC
05/25
05/26
NCT05714657: Shortened Course Adjuvant Radiotherapy Following TORS

Recruiting
2
104
US
Shortened Course Adjuvant Radiotherapy Following TORS
Abramson Cancer Center at Penn Medicine
HPV-Associated Oropharyngeal Squamous Cell Carcinoma
12/25
04/26
NCT06591819: Hypofractionated WPPT With HDR Boost

Recruiting
2
30
US
Hypofractionated Whole Pelvis Proton Therapy with Brachytherapy Boost
Abramson Cancer Center at Penn Medicine
Prostate Cancer
01/26
12/31
GynWPProton, NCT05758688: PROton Therapy for Post Surgical Treatment of GYNecologic Cancer

Recruiting
2
25
US
Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT)
Abramson Cancer Center at Penn Medicine
Cervical Cancer, Uterine Cancer, Endometrial Cancer
05/26
11/26
TRAK-ER, NCT04985266 / 2020-004022-36: A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

Recruiting
2
1100
Europe
Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen, Letrozole, Exemestane, Anastrozole
Royal Marsden NHS Foundation Trust, Pfizer, AstraZeneca, Institute of Cancer Research, United Kingdom, UNICANCER, Gustave Roussy, Cancer Campus, Grand Paris, Invitae Corporation
ER+ Breast Cancer, HER2-negative Breast Cancer
09/27
09/30
NCT05029401: A Study of Oral Ibogaine in Opioid Withdrawal

Completed
1/2
116
Europe
DMX-1002, Ibogaine Hydrochloride, Placebo, Microcrystalline cellulose
atai Therapeutics, Inc., MAC Clinical Research, ERT: Clinical Trial Technology Solutions, Hammersmith Medicines Research
Opiate Withdrawal Syndrome
01/24
01/24
PROSPER, NCT06244771: A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Recruiting
1/2
403
US
FMC-376
Frontier Medicines Corporation
Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer, KRAS G12C, Pancreatic Cancer
10/27
04/28
NCT05450549: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants

Completed
1
47
Europe
DNL919, Placebo
Denali Therapeutics Inc., Takeda
Healthy Participant
06/23
06/23
NCT03832985: Pediatric Reporting of Adult-Onset Genomic Results

Completed
1
427
US
Receive an adult-onset result, Receive a pediatric-onset result, Control - No Result
Geisinger Clinic, National Human Genome Research Institute (NHGRI)
Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome, Familial Hypercholesterolemia
10/24
10/24
MV371 LAI FiH, NCT06558643: Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants

Recruiting
1
24
Europe
MMV371 LAI, Placebo for MMV371
Medicines for Malaria Venture, Quotient Sciences, The Doctors Laboratory
Malaria,Falciparum
03/25
03/25
NCT06639724: Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

Recruiting
1
36
US
Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
University of California, San Diego, Rigel Pharmaceuticals
Pancreatic Ductal Adenocarcinoma (PDAC)
06/27
12/28
NCT06586255: Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer

Recruiting
1
10
US
Concurrent Immunotherapy and Radiation Therapy
Abramson Cancer Center at Penn Medicine
Urothelial Carcinoma Bladder, Bladder Cancer
04/27
04/27
ENHANCE, NCT05866471: The Study: TaVNS and Psilocybin

Recruiting
1
108
US
Psilocybin, Psilocybine, Psilocibin, Filament Health Psilocybin, PEX010, Transcutaneous auricular Vagus Nerve Stimulation (taVNS), Psychosocial Support Alone, Sham taVNS
University of Wisconsin, Madison, Tiny Blue Dot Foundation
Healthy, Psychedelic Experiences, Vagus Nerve Stimulation
11/27
01/28
NCT06129084: A Study to Compare the Results of FGFR Testing by Either CtDNA Blood Testing or Standard Tumor Tissue Testing

Recruiting
N/A
260
Canada
FGFR Testing
Bernie Eigl, Vancouver Prostate Centre, Lady Davis Institute, Bladder Cancer Canada
Metastatic Bladder Cancer, Metastatic Urothelial Carcinoma
03/25
05/25
Focused-PPC, NCT05280951: An Integrated Postpartum Care, Education, and Support Model for Women in Ghana

Recruiting
N/A
192
RoW
Focused-PPC Care, Usual Care
University of Notre Dame, Savana Signatures, Indiana University School of Medicine
Postpartum Care
01/23
06/23
DIAGNOSE CRDS, NCT06188689: Evaluation of A Clinical Diagnostic Test for CRDS

Recruiting
N/A
400
Europe, Canada, RoW
Pacing
Population Health Research Institute, Canadian Institutes of Health Research (CIHR)
Calcium Release Deficiency Syndrome (CRDS)
12/25
03/26
HBS Ancillary, NCT04794543: Effects of Using E-Cigarettes on Lungs in People With HIV

Completed
N/A
23
US
Pennington Biomedical Research Center, National Institute of General Medical Sciences (NIGMS)
Hiv, Lung Injury
08/23
12/23
CAE-E, NCT04622150: Effectiveness RCT of Customized Adherence Enhancement

Recruiting
N/A
190
US
Customized Adherence Enhancement (CAE), Enhanced Treatment as Usual (eTAU)
Case Western Reserve University, National Institute of Mental Health (NIMH)
Bipolar Disorder
11/25
05/26
TECHWISE, NCT06664944: Technology Exposure and Child Health: Wellness Impact and Social Effects: an Observational Product Registry Study

Recruiting
N/A
1000
US
Aura
Mood, Depression Disorders, Anxiety Disorders, Sleep, Eating Disorders, Physical Activity, Loneliness, Stress
12/25
12/25
CRDS Registry, NCT06508164: International

Recruiting
N/A
500
Canada
Population Health Research Institute, Canadian Institutes of Health Research (CIHR)
Calcium Release Deficiency Syndrome
12/50
12/50
NCT06776406: Head Stabilization in Whole Brain RT

Not yet recruiting
N/A
20
US
Freedom Pursuit Robotic Platform
Abramson Cancer Center at Penn Medicine
Brain Cancer
02/27
02/27
RERUN, NCT06809764: Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC

Not yet recruiting
N/A
150
RoW
No drug
Daiichi Sankyo
Non-small Cell Lung Cancer
02/27
02/27
NCT06659900: Community Vital Signs (CVS): an Integrated Community-Based Approach to Identify Undiagnosed Hypertension in Nigeria

Not yet recruiting
N/A
24000
RoW
CORE Plus (+), CORE
Oregon Health and Science University, University of Nigeria Nsukka
Hypertension
06/27
06/27
IMPACT, NCT04330833: Informational Meetings for Planning and Coordinating Treatment

Active, not recruiting
N/A
110
US
Novel Communication Intervention, Enhanced Usual Care Parent Education
Indiana University, National Cancer Institute (NCI)
End of Life, Communication, Cancer Metastatic
04/25
04/25
ASPIRE-II, NCT06668350: Attitudes and Perceptions Attitudes and Smoking Perceptions in the Real Environment -II

Not yet recruiting
N/A
190
US
Smoking outcomes
University of Oklahoma
Cigarillo Flavor
02/29
06/29
NCT06812117: A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)

Not yet recruiting
N/A
720
RoW
No Drug
Daiichi Sankyo
Diabetic Peripheral Neuropathic Pain
02/26
04/26
Safe-De, NCT05058183: Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer

Recruiting
N/A
400
Europe
ctDNA
Royal Marsden NHS Foundation Trust, Massachusetts General Hospital, Natera, Inc.
Breast Cancer
12/25
12/28
 

Download Options